Thomas H. Lee Advisors, Llc Sells 1,179 Shares of Syneos Health, Inc. (NASDAQ:SYNH) Stock

Syneos Health, Inc. (NASDAQ:SYNH) Director Thomas H. Lee Advisors, Llc sold 1,179 shares of the stock in a transaction that occurred on Monday, June 7th. The stock was sold at an average price of $81.20, for a total value of $95,734.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Thomas H. Lee Advisors, Llc also recently made the following trade(s):

  • On Wednesday, May 12th, Thomas H. Lee Advisors, Llc sold 89 shares of Syneos Health stock. The stock was sold at an average price of $81.04, for a total value of $7,212.56.

SYNH opened at $84.10 on Friday. Syneos Health, Inc. has a 12 month low of $50.26 and a 12 month high of $90.10. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 0.89. The firm has a market cap of $8.77 billion, a PE ratio of 44.73 and a beta of 1.84. The firm has a 50 day simple moving average of $84.09.

Syneos Health (NASDAQ:SYNH) last issued its quarterly earnings results on Thursday, April 29th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.17. Syneos Health had a return on equity of 10.23% and a net margin of 4.44%. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.19 billion. As a group, equities analysts predict that Syneos Health, Inc. will post 3.81 EPS for the current fiscal year.

A number of research analysts have commented on the company. Truist Securities increased their target price on Syneos Health from $88.00 to $104.00 and gave the stock a “buy” rating in a report on Wednesday, June 2nd. Citigroup raised their price target on Syneos Health from $80.00 to $85.00 in a report on Friday, February 19th. KeyCorp raised their price target on Syneos Health from $76.00 to $90.00 and gave the stock an “overweight” rating in a report on Monday, March 8th. Barclays assumed coverage on Syneos Health in a report on Monday, March 8th. They issued an “equal weight” rating and a $84.00 price target on the stock. Finally, Mizuho raised their price target on Syneos Health from $82.00 to $90.00 and gave the stock a “buy” rating in a report on Friday, April 30th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $83.50.

Several hedge funds have recently modified their holdings of SYNH. Thrivent Financial for Lutherans increased its position in shares of Syneos Health by 139.1% during the 1st quarter. Thrivent Financial for Lutherans now owns 1,707,734 shares of the company’s stock valued at $129,531,000 after purchasing an additional 993,476 shares during the period. BlackRock Inc. increased its position in shares of Syneos Health by 11.3% during the 1st quarter. BlackRock Inc. now owns 8,316,979 shares of the company’s stock valued at $630,844,000 after purchasing an additional 844,278 shares during the period. Norges Bank acquired a new position in shares of Syneos Health during the 4th quarter valued at $50,763,000. Artemis Investment Management LLP increased its position in shares of Syneos Health by 86.0% during the 1st quarter. Artemis Investment Management LLP now owns 714,464 shares of the company’s stock valued at $54,195,000 after purchasing an additional 330,429 shares during the period. Finally, Bank of New York Mellon Corp increased its position in shares of Syneos Health by 20.5% during the 4th quarter. Bank of New York Mellon Corp now owns 1,768,756 shares of the company’s stock valued at $120,505,000 after purchasing an additional 300,770 shares during the period. Institutional investors own 90.68% of the company’s stock.

About Syneos Health

Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process.

Further Reading: How is diluted EPS different from basic EPS?

Insider Buying and Selling by Quarter for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.